Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N, Rostaing L, Cassuto E, Villemain F, Moal MC, Ladrière M, Barrou B, Ducloux D, Chaouche K, Quéré S, Di Giambattista F, Be F. Kamar N, et al. Among authors: di giambattista f. Clin Nephrol. 2012 Feb;77(2):126-36. doi: 10.5414/CN107227. Clin Nephrol. 2012. PMID: 22257543 Clinical Trial.
Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E; RAD A2420 Study Group. Dantal J, et al. Among authors: di giambattista f. Transpl Int. 2010 Nov;23(11):1084-93. doi: 10.1111/j.1432-2277.2010.01094.x. Epub 2010 Aug 19. Transpl Int. 2010. PMID: 20500493 Free article. Clinical Trial.
Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
Albano L, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, Tetaz R, Moal MC, Kamar N, Legendre C, Quéré S, Di Giambattista F, Terpereau A, Dantal J. Albano L, et al. Among authors: di giambattista f. Ann Transplant. 2012 Jan-Mar;17(1):58-67. doi: 10.12659/aot.882637. Ann Transplant. 2012. PMID: 22466910 Clinical Trial.
Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity study.
Thierry A, Mourad G, Büchler M, Choukroun G, Toupance O, Kamar N, Villemain F, Le Meur Y, Legendre C, Merville P, Kessler M, Heng AE, Moulin B, Queré S, Di Giambattista F, Lecuyer A, Touchard G. Thierry A, et al. Among authors: di giambattista f. J Transplant. 2014;2014:171898. doi: 10.1155/2014/171898. Epub 2014 Mar 5. J Transplant. 2014. PMID: 24829794 Free PMC article.
Diabetes mellitus after kidney transplantation: a French multicentre observational study.
Kamar N, Mariat C, Delahousse M, Dantal J, Al Najjar A, Cassuto E, Lefrançois N, Cointault O, Touchard G, Villemain F, Di Giambattista F, Benhamou PY; Diapason Study Group. Kamar N, et al. Among authors: di giambattista f. Nephrol Dial Transplant. 2007 Jul;22(7):1986-93. doi: 10.1093/ndt/gfm011. Epub 2007 Mar 29. Nephrol Dial Transplant. 2007. PMID: 17400559
Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA.
Rostaing L, Hertig A, Albano L, Anglicheau D, Durrbach A, Vuiblet V, Moulin B, Merville P, Hazzan M, Lang P, Touchard G, Hurault deLigny B, Quéré S, Di Giambattista F, Dubois YC, Rondeau E; CERTITEM Study Group. Rostaing L, et al. Among authors: di giambattista f. Am J Transplant. 2015 May;15(5):1303-12. doi: 10.1111/ajt.13132. Epub 2015 Mar 23. Am J Transplant. 2015. PMID: 25808994 Free article. Clinical Trial.
Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E, Neau-Cransac M, Durand F, Houssel-Debry P, Vanlemmens C, Pageaux G, Hardwigsen J, Eyraud D, Calmus Y, Di Giambattista F, Dumortier J, Conti F. Saliba F, et al. Among authors: di giambattista f. Am J Transplant. 2017 Jul;17(7):1843-1852. doi: 10.1111/ajt.14212. Epub 2017 Mar 10. Am J Transplant. 2017. PMID: 28133906 Free article. Clinical Trial.
Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J; RAD A2420 Study Group. Albano L, et al. Among authors: di giambattista f. Transplantation. 2009 Jul 15;88(1):69-76. doi: 10.1097/TP.0b013e3181aa7d87. Transplantation. 2009. PMID: 19584683 Clinical Trial.
CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
Thibault G, Paintaud G, Legendre C, Merville P, Coulon M, Chasseuil E, Ternant D, Rostaing L, Durrbach A, Di Giambattista F, Büchler M, Lebranchu Y. Thibault G, et al. Among authors: di giambattista f. Transpl Int. 2016 Feb;29(2):184-95. doi: 10.1111/tri.12688. Epub 2015 Oct 8. Transpl Int. 2016. PMID: 26369526 Free article. Clinical Trial.
13 results